ACTG:A5223 SEX DIFFS IN LOPINAVIR/RITONAVIR PHRMCOKIN AMNG HIV1 INFCTD MEN&WOMEN

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究将观察服用卡莱特拉韦(也称为洛匹那韦/利托那韦)的男性和女性的血液中的药物水平，看看他们是否不同。这项研究还将试图找出年龄、体重、种族/民族和其他药物等因素如何影响这些药物水平的结果。最近的科学研究表明，越来越多的女性感染了艾滋病毒。据认为，全世界感染艾滋病毒/艾滋病的人中有一半是妇女。然而，大多数最初关于用于治疗艾滋病毒感染的药物的安全性和有效性的研究并没有包括很多女性。最近的研究表明，艾滋病毒药物对男性和女性的影响可能不同。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study will look at drug levels in the blood in both men and women taking Kaletra¿ (also known as lopinavir/ritonavir) to see if they are different. This study will also try to find out how factors such as age, weight, race/ethnicity, and other medications may affect these drug level results. Recent scientific studies have suggested that more and more women are being infected with the HIV virus. It is thought that half of all the people in the world living with HIV/AIDS are women. However, most of the initial research studies on the safety and effectiveness of drugs used for treatment of HIV infection did not include a lot of women. Recent research suggests that HIV medications may affect men and women differently.